Abstracts tagged "Autoantibodies and autoimmune diseases"

Abstract Number: 790 • 2019 ACR/ARP Annual Meeting
Can High ANA Titre Combined with Clinical Features Predict Developing Autoimmune Conditions in Children?
Ovgu Kul Cinar¹, Charlene Foley ², Ali Al-Hussain ³, Kimberly Gilmour ⁴, Matthew Buckland ⁴ and Muthana Al-Obaidi ⁵, ¹Great Ormond Street Hospital, Lonodn, United Kingdom, ²Great Ormond Street Hospital, London, Ireland, ³Great Ormond Street Hospital, London, United Kingdom, ⁴Great Ormond Street Hospital NHS Trust, Camelia Botnar Laboratories, London, United Kingdom, ⁵Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Antinuclear antibodies (ANA) are autoantibodies that recognise cellular antigens found predominantly in the cell nucleus. They are associated with numerous autoimmune diseases such as…
Abstract Number: 2618 • 2019 ACR/ARP Annual Meeting
Anti-RNPC-3 Antibodies Are Associated with Nuclear Speckled Immunofluorescence Pattern and Enriched in Triple Negative Systemic Sclerosis Patients
Michael Mahler¹, Fabrece Roup ¹, Chelsea Bentow ¹, Marie Hudson ², Murray Baron ³, May Choi ⁴ and Marvin Fritzler ⁵, ¹Inova Diagnostics, San Diego, CA, ²Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ³Jewish General Hospital, McGill University, Montreal, Canada, ⁴Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁵Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Anti-nuclear antibodies (ANA) are present in approximately 90% of sera from systemic sclerosis (SSc) patients and play an important diagnostic and prognostic role in…
Abstract Number: 2883 • 2018 ACR/ARHP Annual Meeting
Testing for Anti-Microbial Antibodies with Cross-Reactivity to Human Tissue in Autoimmune Diseases
Peilin Zhang, Lawrence Minardi, J. Todd Kuenstner and Stephen Zekan, PZM Diagnostics, LLC, Charleston, WV
Background/Purpose: Autoantibodies are defining features of autoimmune diseases. How and why the autoantibodies are produced and how these autoantibodies relate to pathogenesis is poorly understood.…
Abstract Number: 1069 • 2017 ACR/ARHP Annual Meeting
Significantly Elevated Serum Protein-Adduction with 4-Hydroxy-2-Nonenal but Not Malondialdehyde in Sjogren’s Syndrome
Biji T Kurien^1,2,3, Sona Nuguri⁴, Bre'ana Byrd⁵, Joey Maher⁶, Rohit Thomas⁴, Huyen Tran⁷ and R. Hal Scofield⁸, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Oklahoma School of Science and Mathematics, Oklahoma City, OK, ⁵University of Central Oklahoma, Edmond, OK, ⁶University of Oklahoma, Norman, OK, ⁷University of Oklahoma Health Sciences Center, Edmond, OK, ⁸Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a chronic inflammatory, autoimmune disorder characterized by diminished lacrimal and salivary gland secretion resulting in keratoconjunctivitis sicca and xerostomia. Autoantibodies,…
Abstract Number: 776 • 2015 ACR/ARHP Annual Meeting
Sensitivity of Antinuclear Antibody By Immunofluorescence Testing for Detection of Anti-Ro/SSA Antibodies
Ivan Alcantara-Arreola¹, Nina Tello-Winniczuk² and Alejandro Diaz-Borjon³, ¹Hospital Angeles Lomas, Huixquilucan, Mexico, ²Division of Internal Medicine / Rheumatology, Hospital Angeles Lomas, Huixquilucan, Mexico, ³Med/Div of Rheumatology, Hospital Angeles Lomas, Huixquilucan, Mexico
Background/Purpose: A positive ANA test is a diagnostic criterion for several rheumatic diseases, although it may appear in other autoimmune disorders and healthy individuals. An…
Abstract Number: 4 • 2014 ACR/ARHP Annual Meeting
Detection of Anti-Beta2glycoprotein I Domain 1 Antibodies By an Automated Chemiluminescence Assay in a Cohort of 400 Clinically Characterized Consecutive Routine Samples
Laura Andreoli¹, Alessandra Zanola¹, Cecilia Nalli¹, Flavio Allegri¹, Michael Mahler², Gary Norman³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²9900 Old Grove road, INOVA Diagnostics, San Diego, CA, ³INOVA Diagnostics, San Diego, CA
Background/Purpose: Several studies suggested that antibodies to Domain 1 of beta2glycoprotein I (a-B2GPI-D1) represent a promising biomarker for the diagnosis and risk assessment of Antiphospholipid…
Abstract Number: 209 • 2012 ACR/ARHP Annual Meeting
Clinical Study of Determination of Myositis-Associated Autoantibodies in Japanese Patients with Connective Tissue Diseases except Autoimmune Myositis
Toshio Kawamoto¹, Masakazu Matsushita¹, Ken Yamaji¹, Naoto Tamura¹ and Yoshinari Takasaki², ¹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Juntendo University, Tokyo, Japan
Background/Purpose: Anti-Jo-1 antibody is detected in the sera of patients with polymyositis/dermatomyositis (PM/DM). The antigen to which this antibody is directed is histidyl-tRNA synthase, an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].